EORTC study shows radiotherapy and surgery provide regional control for breast cancer patients

EORTC AMAROS trial presented at ASCO 2013

2013-06-03

(Press-News.org) Final analysis of the EORTC 10981-22023 AMAROS (After Mapping of the Axilla: Radiotherapy Or Surgery?) trial has shown that both axillary lymph node dissection and axillary radiotherapy provide excellent regional control for breast cancer patients with a positive sentinel node biopsy. The AMAROS trial also found that axillary radiotherapy reduces the risk of short term and long-term lymphoedema as compared to axillary lymph node dissection.

Prof. Emiel J. Rutgers of The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis in Amsterdam, the EORTC Breast Cancer Group, and principal investigator of this study says, "Sentinel node biopsy has become the standard procedure for assessing axillary lymph node status for cN0 breast cancer patients. At the start of this trial the question was whether axillary lymph node dissection should remain the standard treatment in case of a tumor positive sentinel node."

From 2001 to 2010, 4806 patients who were diagnosed with invasive breast cancer were enrolled in this phase III non-inferiority trial, and randomized for their axillary treatment in case the sentinel node biopsy was positive. Of these, 3131 patients had negative biopsies and 250 patients had a different sentinel node outcome. Thus, out of 1425 patients with positive node, axillary lymph node dissection was to be used in 744 patients, and axillary radiotherapy in 681 patients.

Dr. Geertjan van Tienhoven of the Academisch Medisch Centrum - Universiteit van Amsterdam and principal investigator on behalf of the EORTC Radiation Oncology Group says, "Although axillary lymph node dissection provides excellent regional control, it was known to cause harmful side effects. Axillary radiotherapy instead of axillary lymph node dissection was hypothesized to provide comparable regional control and perhaps fewer side effects in this particular group of patients."

The primary endpoint of this EORTC trial was 5-year axillary recurrence rate. At a median follow up of 6.1 years, this rate was 0.54% (4 out of 744 patients) after axillary lymph node dissection and 1.03% (7 out of 681 patients) after axillary radiotherapy. Due to the unexpectedly low number of events, the non-inferiority test was underpowered. The axillary recurrence rate for patients with a negative sentinel node biopsy was 0.8% (25 out of 3131 patients).

Secondary endpoints were overall survival, disease-free survival, quality of life, shoulder movement and lymphoedema at one and five years. No significant differences in overall or disease free survival were observed between the two treatment arms. Five year estimates for overall survival were 93.3% for the arm receiving axillary lymph node dissection and 92.5% for patients in the axillary radiotherapy arm (p=0.34), and for disease-free survival the five year estimates were 86.9% for axillary lymph node dissection and 82.6% for axillary radiotherapy (p=0.18).

Lymphoedema, a swelling of tissue (typically occurring in the arm), occurred more often following axillary lymph node dissection, 40% at one year and 28% at five years, than after axillary radiotherapy, 22% at one year and 14% at five years (p END

ELSE PRESS RELEASES FROM THIS DATE:

Songbirds may give insight to nature vs. nuture

2013-06-03

VIDEO: This is the article as it appears in JoVE Behavior. Click here for more information. On June 3rd, JoVE will publish a research technique that allows neural imaging of auditory stimuli in songbirds via MRI. The technique, developed by Dr. Annemie Van der Linden and her laboratory at the University of Antwerp in Belgium, will be one of the first published in JoVE Behavior, a new section of the video journal that focuses on observational and experimental techniques that ...

Scientists develop new technique to selectively dampen harmful immune responses

2013-06-03

LA JOLLA, CA – June 3, 2013 – The human immune system is remarkably efficient, but sometimes its attack is misdirected, leading to allergies, autoimmune diseases and rejection of transplant organs and therapeutic drugs. Current immune suppressants have major drawbacks, but a team from The Scripps Research Institute (TSRI) has demonstrated a new technique that may lead to a better way to selectively repress unwanted immune reactions without disabling the immune system as a whole. As a proof of principle, the study, reported online ahead of print on June 3, 2013, by the ...

Lightest exoplanet imaged so far?

2013-06-03

Although nearly a thousand exoplanets have been detected indirectly — most using the radial velocity or transit methods [1] — and many more candidates await confirmation, only a dozen exoplanets have been directly imaged. Nine years after ESO's Very Large Telescope captured the first image of an exoplanet, the planetary companion to the brown dwarf 2M1207 (eso0428 - http://www.eso.org/public/news/eso0428/), the same team has caught on camera what is probably the lightest of these objects so far [2][3]. "Direct imaging of planets is an extremely challenging technique that ...

Addressing biodiversity data quality is a community-wide effort

2013-06-03

Improving data quality in large online data access facilities depends on a combination of automated checks and capturing expert knowledge, according to a paper published in the open-access journal Zookeys. The authors, from the Atlas of Living Australia (ALA) and the Global Biodiversity Information Facility (GBIF) welcome a recent paper by Mesibov (2013) highlighting errors in millipede data, but argue that addressing such issues requires the joint efforts of 'aggregators' and the wider expert community. The paper notes that aggregations of data openly exposed in facilities ...

Molecular switch for cheaper biofuel

2013-06-03

Lignocellulosic waste such as sawdust or straw can be used to produce biofuel – but only if the long cellulose and xylan chains can be successfully broken down into smaller sugar molecules. To do this, fungi are used which, by means of a specific chemical signal, can be made to produce the necessary enzymes. Because this procedure is, however, very expensive, Vienna University of Technology has been investigating the molecular switch that regulates enzyme production in the fungus. As a result, it is now possible to manufacture genetically modified fungi that produce the ...

Clinicians often wait for 'red flags' before discussing elderly driving

2013-06-03

AURORA, Colo. (June 3, 2013) – Clinicians often wait too long before talking to elderly patients about giving up driving even though many may be open to those discussions earlier, according to a new study from the University of Colorado School of Medicine and the CU College of Nursing. "These conversations often don't happen until clinicians see a 'red flag' which could mean an accident or some physical problem that makes driving more difficult for the elderly," said Marian Betz, MD, MPH, at the CU School of Medicine and lead author of the study. "But what's interesting ...

'Back to sleep' does not affect baby's ability to roll

2013-06-03

VIDEO: Baby Logan shows off his healthy development by rolling from his tummy to his back. University of Alberta researcher Johanna Darrah, a professor of physical therapy, says infants develop the ability... Click here for more information. (Edmonton) Baby, keep on rolling. A campaign to put babies to bed on their backs to reduce the risk of sudden infant death syndrome has not impaired infants' rolling abilities, according to University of Alberta research. Johanna Darrah, ...

Salt gets under your skin

2013-06-03

It's time to expand the models for blood pressure regulation, according to clinical pharmacologist Jens Titze, M.D. Titze and his colleagues have identified a new cast of cells and molecules that function in the skin to control sodium balance and blood pressure. "Hypertension research has traditionally focused on the kidney, blood vessels and brain," said Titze, associate professor of Medicine at Vanderbilt University. "But despite massive research efforts, we still do not understand in more than 90 percent of our patients why their blood pressure is elevated. We thought ...

Dartmouth researchers test safety of Nivolumab in kidney cancer

2013-06-03

(Lebanon, NH, 5/24/13) — Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center will present a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with metastatic renal cell carcinoma (mRCC) at the ASCO Annual Meeting on June 3, 2013. Metastatic renal cell carcinoma or kidney cancer is the seventh most common cancer, leading to approximately 116,000 deaths annually worldwide. In roughly one-quarter of those with mRCC, the cancer has already spread or metastasized at diagnosis. Nivolumab ...

Cancer drug shortages hit 83 percent of US oncologists

2013-06-03

CHICAGO – Eighty-three percent of cancer doctors report that they've faced oncology drug shortages, and of those, nearly all say that their patients' treatment has been impacted, according to a study from researchers at the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 2013 annual meeting of the American Society of Clinical Oncology (Abstract #CRA6510). The results showed that shortages – which have hit especially hard among drugs to treat pediatric, gastrointestinal and blood cancers – have ...

EORTC study shows radiotherapy and surgery provide regional control for breast cancer patients

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: